Login to Your Account

China's low level of reimbursement drives biopharma markets west

By Shannon Ellis
Staff Writer

Monday, November 7, 2016

SHANGHAI – During the ChinaTrials meeting in Shanghai last week it was clear that many China biopharmas view entering the U.S. market as necessary for long-term success. When looking ahead, they lack confidence the China market will sufficiently reward investments in new drugs.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription